- Home
- TARA vs PLX Comparison
TARA vs PLX Comparison
Compare TARA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- PLX
- Stock Information
- Founded
- TARA N/A
- PLX 1993
- Country
- TARA United States
- PLX United States
- Employees
- TARA N/A
- PLX N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TARA Health Care
- PLX Health Care
- Exchange
- TARA Nasdaq
- PLX Nasdaq
- Market Cap
- TARA 126.5M
- PLX 122.6M
- IPO Year
- TARA N/A
- PLX 1998
- Fundamental
- Price
- TARA $2.80
- PLX $1.47
- Analyst Decision
- TARA Strong Buy
- PLX Strong Buy
- Analyst Count
- TARA 7
- PLX 1
- Target Price
- TARA $20.67
- PLX $15.00
- AVG Volume (30 Days)
- TARA 478.9K
- PLX 1.2M
- Earning Date
- TARA 08-05-2025
- PLX 08-13-2025
- Dividend Yield
- TARA N/A
- PLX N/A
- EPS Growth
- TARA N/A
- PLX N/A
- EPS
- TARA N/A
- PLX 0.05
- Revenue
- TARA N/A
- PLX $59,764,000.00
- Revenue This Year
- TARA N/A
- PLX $65.02
- Revenue Next Year
- TARA N/A
- PLX $57.34
- P/E Ratio
- TARA N/A
- PLX $30.63
- Revenue Growth
- TARA N/A
- PLX 0.18
- 52 Week Low
- TARA $1.60
- PLX $0.82
- 52 Week High
- TARA $10.48
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- TARA 39.61
- PLX 42.57
- Support Level
- TARA $3.12
- PLX $1.32
- Resistance Level
- TARA $3.10
- PLX $1.67
- Average True Range (ATR)
- TARA 0.19
- PLX 0.11
- MACD
- TARA -0.01
- PLX 0.03
- Stochastic Oscillator
- TARA 1.39
- PLX 41.86
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.